Related Experiment Video
Updated: Dec 25, 2025

12:05
Co-staining Blood Vessels and Nerve Fibers in Adipose Tissue
Published on: February 13, 2019
9.8K
Angiogenesis in obesity
Priya Nijhawans1, Tapan Behl1, Shaveta Bhardwaj2
1Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Summary
Angiogenesis, the growth of new blood vessels, plays a key role in obesity development. Targeting this process with anti-angiogenic therapies may offer a novel strategy for obesity treatment.
Area of Science:
- Physiology
- Metabolic Diseases
- Vascular Biology
Background:
- Obesity is a complex metabolic condition driven by factors like high-calorie diets and inactivity.
- Excess adipose tissue accumulation exacerbates obesity and related health complications.
- Angiogenesis, the formation of new blood vessels, is increasingly recognized as a significant factor in obesity's progression.
Purpose of the Study:
- To elucidate the extrinsic role of angiogenesis in the development and progression of obesity.
- To explore the intricate relationship between adipose tissue expansion and vascularization.
Main Methods:
- Review of existing literature on angiogenesis and obesity.
- Analysis of the molecular mechanisms linking adipose tissue, inflammation, and endothelial cell proliferation.
- Examination of the potential of angiostatic agents in combating obesity.
Main Results:
- Obesity is characterized by the enlargement of white adipose tissue (WAT), leading to increased endothelial cell proliferation and the formation of new capillaries.
- Inflammatory cytokines and intracellular signaling pathways within adipose tissue contribute to obesity-related angiogenesis.
- Several angiostatic molecules, including endostatin, angiostatin, and TNP-470, have been investigated for their potential to inhibit obesity.
Conclusions:
- Adipose tissue actively promotes blood capillary growth, with endothelial cells in turn stimulating pre-adipocyte proliferation.
- Modulating angiogenesis and utilizing angiostatic substances present a promising therapeutic avenue for managing and potentially reversing obesity progression.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
3.2K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Mechanism of Angiogenesis
6.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
187
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
187
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
118
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
118

